Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
5(45%)
Results Posted
100%(2 trials)
Terminated
2(18%)

Phase Distribution

Ph not_applicable
2
18%
Ph phase_1
6
55%
Ph phase_2
1
9%
Ph phase_3
2
18%

Phase Distribution

6

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
6(54.5%)
Phase 2Efficacy & side effects
1(9.1%)
Phase 3Large-scale testing
2(18.2%)
N/ANon-phased studies
2(18.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

5

trials recruiting

Total Trials

11

all time

Status Distribution
Active(5)
Completed(2)
Terminated(3)
Other(1)

Detailed Status

Recruiting3
Active, not recruiting2
Completed2
Terminated2
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
5
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 16 (54.5%)
Phase 21 (9.1%)
Phase 32 (18.2%)
N/A2 (18.2%)

Trials by Status

unknown19%
withdrawn19%
active_not_recruiting218%
completed218%
recruiting327%
terminated218%

Recent Activity

5 active trials
Showing 5 of 11
recruitingphase_3

Efficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma

NCT07705243
recruitingphase_1

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

NCT06265727
active_not_recruitingphase_3

A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma

NCT05751928
active_not_recruitingphase_1

Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma

NCT05607953
recruitingnot_applicable

Anti PD-1 Plus Postbiotic Versus Anti PD-1 Alone in Locally Advanced or Metastatic, Treatment naïve, Cutaneous Melanoma Study

NCT07050940
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT07705243Phase 3

Efficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma

Recruiting
NCT06265727Phase 1

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

Recruiting
NCT05751928Phase 3

A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma

Active Not Recruiting
NCT05607953Phase 1

Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma

Active Not Recruiting
NCT07050940Not Applicable

Anti PD-1 Plus Postbiotic Versus Anti PD-1 Alone in Locally Advanced or Metastatic, Treatment naïve, Cutaneous Melanoma Study

Recruiting
NCT04171141Phase 1

Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

Terminated
NCT03009058Phase 1

Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer

Terminated
NCT06676293Not Applicable

Compassionate Use of Asparaginase and Pembrolizumab Combination Theaapy for Nasopharyngeal Carcinoma

Completed
NCT02658981Phase 1

Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)

Completed
NCT04001101Phase 2

Anti-PD-1 +/- RT for MSI-H Solid Tumors

Withdrawn
NCT04072900Phase 1

A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma

Unknown

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11